These findings highlight DC dysfunction as a central element of EGFR‐driven immune evasion and underline the therapeutic potential of targeting DC maturation to overcome immune resistance in EGFR‐mutant NSCLC (Figure 9). This evidence concerns the gene EGFR and non-small cell lung carcinoma.